REMEGEN (09995) experienced a significant surge in its stock price, soaring 8.86% during Friday's trading session in Hong Kong. This impressive gain comes as part of a broader rally in the biotech sector, with several companies in the industry posting substantial increases.
The biotech sector in Hong Kong saw widespread gains, with companies like Cutia Therapeutics leading the pack with a 14% increase. Other notable performers included Antengene (up 13%), HBM Holdings and TransThera Sciences (both up 9%), and CARsgen Therapeutics (up 7%). REMEGEN's 8.86% rise positioned it firmly among the top performers in this sector-wide upswing, reflecting strong investor confidence in the biotech industry and REMEGEN's potential within it.